{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:19:32Z","timestamp":1791674372246,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011541","name":"Division of Cancer Epidemiology and Genetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Microbe"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.lanmic.2026.101401","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:20:31Z","timestamp":1778851231000},"page":"101401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7308-950X","authenticated-orcid":false,"given":"John T","family":"Schiller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda C","family":"Kines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia M","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"\u00c7uburu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9e R","family":"Kreimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas R","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanmic.2026.101401_bib1","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel","year":"2019","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101401_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/INF.0000000000002569","article-title":"Systematic review and meta-analysis of postlicensure observational studies on human papillomavirus vaccination and autoimmune and other rare adverse events","volume":"39","author":"Willame","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.lanmic.2026.101401_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QCO.0000000000000343","article-title":"Future prospects for new vaccines against sexually transmitted infections","volume":"30","author":"Gottlieb","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101401_bib4","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/21645515.2020.1732166","article-title":"Hepatitis B vaccine development and implementation","volume":"16","author":"Zhao","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanmic.2026.101401_bib5","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0268","article-title":"Tumour virus vaccines: hepatitis B virus and human papillomavirus","volume":"372","author":"Stanley","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.lanmic.2026.101401_bib6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0140-6736(24)01097-3","article-title":"Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature","volume":"404","author":"Wei","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101401_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lanmic.2026.101401_bib8","article-title":"Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"de Sanjos\u00e9","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"suppl 2","key":"10.1016\/j.lanmic.2026.101401_bib9","doi-asserted-by":"crossref","first-page":"S367","DOI":"10.1093\/infdis\/jiaa621","article-title":"Human papillomavirus vaccines","volume":"224","author":"Markowitz","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101401_bib10","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/2159-8290.CD-11-0131","article-title":"Prevention of persistent human papillomavirus infection by an HPV16\/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica","volume":"1","author":"Herrero","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.lanmic.2026.101401_bib11","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(21)00453-8","article-title":"Vaccine efficacy against persistent human papillomavirus (HPV) 16\/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study","volume":"22","author":"Basu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lanmic.2026.101401_bib12","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060993","article-title":"Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety","volume":"152","author":"Restrepo","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.lanmic.2026.101401_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0264-410X(00)00224-3","article-title":"Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory","volume":"19","author":"Banatvala","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101401_bib14","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lanmic.2026.101401_bib15","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1038\/s41591-023-02658-0","article-title":"Durability of single-dose HPV vaccination in young Kenyan women: randomized controlled trial 3-year results","volume":"29","author":"Barnabas","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101401_bib16","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1056\/NEJMoa2506765","article-title":"Noninferiority of one HPV vaccine dose to two doses","volume":"393","author":"Kreimer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101401_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.15585\/mmwr.mm7012a2","article-title":"Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine - United States, 2003\u20132018","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.lanmic.2026.101401_bib18","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1093\/infdis\/jiaf121","article-title":"Strong herd effects of human papillomavirus vaccination","volume":"232","author":"Chesson","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.lanmic.2026.101401_bib19","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1016\/j.vaccine.2022.06.065","article-title":"Human papillomavirus vaccine effectiveness by number of doses: updated systematic review of data from national immunization programs","volume":"40","author":"Markowitz","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101401_bib20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101401_bib22","doi-asserted-by":"crossref","first-page":"e1473","DOI":"10.1016\/S2214-109X(22)00309-6","article-title":"Immunogenicity and safety of one-dose human papillomavirus vaccine compared with two or three doses in Tanzanian girls (DoRIS): an open-label, randomised, non-inferiority trial","volume":"10","author":"Watson-Jones","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101401_bib23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41541-020-0165-x","article-title":"Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6\/16\/18\/31\/33\/45\/52\/58 induced by bivalent and quadrivalent HPV vaccines","volume":"5","author":"Mariz","year":"2020","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lanmic.2026.101401_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","article-title":"In vivo mechanisms of vaccine-induced protection against HPV infection","volume":"8","author":"Day","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"suppl 1","key":"10.1016\/j.lanmic.2026.101401_bib25","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.jcv.2004.12.006","article-title":"The papillomavirus life cycle","volume":"32","author":"Doorbar","year":"2005","journal-title":"J Clin Virol"},{"key":"10.1016\/j.lanmic.2026.101401_bib26","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.4161\/hv.34408","article-title":"Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus","volume":"10","author":"Herrin","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.lanmic.2026.101401_bib27","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.lanmic.2026.101401_bib28","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/v14102308","article-title":"Revisiting papillomavirus taxonomy: a proposal for updating the current classification in line with evolutionary evidence","volume":"14","author":"Van Doorslaer","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.lanmic.2026.101401_bib29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2010.00912.x","article-title":"Mechanisms that determine plasma cell lifespan and the duration of humoral immunity","volume":"236","author":"Amanna","year":"2010","journal-title":"Immunol Rev"},{"key":"10.1016\/j.lanmic.2026.101401_bib30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41577-019-0244-2","article-title":"B cell memory: building two walls of protection against pathogens","volume":"20","author":"Akkaya","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126817","article-title":"Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine","volume":"50","author":"Carter","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101401_bib32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jncimonographs\/lgae032","article-title":"HPV16\/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trial","volume":"2024","author":"Porras","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.lanmic.2026.101401_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2893.2003.00400.x","article-title":"Hepatitis B vaccine -- do we need boosters?","volume":"10","author":"Banatvala","year":"2003","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.lanmic.2026.101401_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ijc.2910490224","article-title":"Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts","volume":"49","author":"Ghim","year":"1991","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lanmic.2026.101401_bib35","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1126\/science.8248784","article-title":"The influence of antigen organization on B cell responsiveness","volume":"262","author":"Bachmann","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.lanmic.2026.101401_bib36","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1016\/S2214-109X(23)00586-7","article-title":"Comparing one dose of HPV vaccine in girls aged 9\u201314 years in Tanzania (DoRIS) with one dose in young women aged 15\u201320 years in Kenya (KEN SHE): an immunobridging analysis of randomised controlled trials","volume":"12","author":"Baisley","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101401_bib37","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1940-6207.CAPR-13-0203","article-title":"Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial","volume":"6","author":"Safaeian","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.lanmic.2026.101401_bib38","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2214-109X(24)00477-7","article-title":"Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9\u201314 years: results of the long-term extension of the DoRIS randomised trial","volume":"13","author":"Watson-Jones","year":"2025","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lanmic.2026.101401_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28164","article-title":"Vaccine-induced binding and neutralizing antibodies against omicron 6 months after a homologous BNT162b2 booster","volume":"95","author":"Favresse","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.lanmic.2026.101401_bib40","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41541-022-00431-x","article-title":"HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial","volume":"7","author":"Tsang","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lanmic.2026.101401_bib41","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1038\/s41467-025-57443-z","article-title":"Systems serology analysis shows IgG1 and IgG3 memory responses six years after one dose of quadrivalent HPV vaccine","volume":"16","author":"Quang","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanmic.2026.101401_bib42","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0264-410X(96)00062-X","article-title":"Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination","volume":"14","author":"West","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101401_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187661","article-title":"Durability of immunity by hepatitis B vaccine in Japanese health care workers depends on primary response titers and durations","volume":"12","author":"Yoshioka","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.lanmic.2026.101401_bib44","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.vaccine.2009.10.074","article-title":"Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand","volume":"28","author":"Poovorawan","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101401_bib45","first-page":"1442","article-title":"Long-term follow-up of hepatitis B surface antibody levels in subjects receiving universal hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay","volume":"12","author":"Wang","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib46","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.anai.2018.03.017","article-title":"Hepatitis B vaccine nonresponders: possible mechanisms and solutions","volume":"121","author":"Saco","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib47","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/v12080826","article-title":"Progress in the production of virus-like particles for vaccination against hepatitis E virus","volume":"12","author":"Mazalovska","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.lanmic.2026.101401_bib48","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(23)02234-1","article-title":"Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"Huang","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.lanmic.2026.101401_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14760584.2019.1578216","article-title":"Immunological basis for enhanced immunity of nanoparticle vaccines","volume":"18","author":"Kelly","year":"2019","journal-title":"Expert Rev Vaccin"},{"key":"10.1016\/j.lanmic.2026.101401_bib50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41577-024-01073-x","article-title":"Towards a unifying model for B-cell receptor triggering","volume":"25","author":"Degn","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.immuni.2020.08.001","article-title":"Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo","volume":"53","author":"Kato","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.lanmic.2026.101401_bib52","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2414514122","article-title":"In the activation of HPV-specific human B cells HPV-VLP vaccines mimic membrane-associated antigens","volume":"122","author":"Torgbor","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lanmic.2026.101401_bib53","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/s41590-023-01597-9","article-title":"Molecular basis for potent B cell responses to antigen displayed on particles of viral size","volume":"24","author":"Brooks","year":"2023","journal-title":"Nat Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4161\/hv.2.4.2989","article-title":"Evaluation of the thermal stability of Gardasil","volume":"2","author":"Shank-Retzlaff","year":"2006","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.lanmic.2026.101401_bib55","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/CJI.0b013e31818f13c4","article-title":"Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes","volume":"32","author":"Cubas","year":"2009","journal-title":"J Immunother"},{"key":"10.1016\/j.lanmic.2026.101401_bib56","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/eji.201142064","article-title":"Virus-like particles induce robust human T-helper cell responses","volume":"42","author":"Braun","year":"2012","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib57","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.4049\/jimmunol.1103312","article-title":"Innate immunity mediates follicular transport of particulate but not soluble protein antigen","volume":"188","author":"Link","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41423-023-01095-w","article-title":"B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity","volume":"21","author":"Lapuente","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib59","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0264-410X(00)00370-4","article-title":"Immunological analyses of human papillomavirus capsids","volume":"19","author":"Giroglou","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.lanmic.2026.101401_bib60","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/s41467-024-45807-w","article-title":"Global evaluation of lineage-specific human papillomavirus capsid antigenicity using antibodies elicited by natural infection","volume":"15","author":"Kamuyu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.lanmic.2026.101401_bib61","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/molbev\/msw214","article-title":"Transmission between archaic and modern human ancestors during the evolution of the oncogenic human papillomavirus 16","volume":"34","author":"Pimenoff","year":"2017","journal-title":"Mol Biol Evol"},{"key":"10.1016\/j.lanmic.2026.101401_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00779-22","article-title":"Contribution of surface-exposed loops on the HPV16 capsid to antigenic domains recognized by vaccine or natural infection induced neutralizing antibodies","volume":"10","author":"Godi","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.lanmic.2026.101401_bib63","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1073\/pnas.86.18.7059","article-title":"Host-independent evolution and a genetic classification of the hepadnavirus family based on nucleotide sequences","volume":"86","author":"Orito","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lanmic.2026.101401_bib64","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29184","article-title":"Vaccine escape challenges virus prevention: the example of two vaccine-preventable oncogenic viruses","volume":"95","author":"Qu","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.lanmic.2026.101401_bib65","doi-asserted-by":"crossref","first-page":"6929","DOI":"10.1128\/jvi.67.12.6929-6936.1993","article-title":"Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles","volume":"67","author":"Kirnbauer","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.lanmic.2026.101401_bib66","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1128\/JVI.78.2.751-757.2004","article-title":"Efficient intracellular assembly of papillomaviral vectors","volume":"78","author":"Buck","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.lanmic.2026.101401_bib67","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jnci\/djr061","article-title":"Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model","volume":"103","author":"Roberts","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lanmic.2026.101401_bib68","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.lanmic.2026.101401_bib69","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1073\/pnas.0908502106","article-title":"The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding","volume":"106","author":"Kines","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lanmic.2026.101401_bib70","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1073\/pnas.1012861108","article-title":"Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection","volume":"108","author":"Li","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.lanmic.2026.101401_bib71","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/jnci\/djg018","article-title":"Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles","volume":"95","author":"Nardelli-Haefliger","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.lanmic.2026.101401_bib72","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/s41541-025-01266-y","article-title":"Immunization with VLP-based vaccines induces high IgG antibody titers in dermal interstitial fluid","volume":"10","author":"Francian","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lanmic.2026.101401_bib73","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1056\/NEJMoa0909537","article-title":"Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males","volume":"364","author":"Giuliano","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lanmic.2026.101401_bib74","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1128\/JVI.06093-11","article-title":"A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection","volume":"85","author":"Longet","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.lanmic.2026.101401_bib75","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.it.2022.07.011","article-title":"Single-dose HPV vaccine immunity: is there a role for non-neutralizing antibodies?","volume":"43","author":"Quang","year":"2022","journal-title":"Trends Immunol"},{"key":"10.1016\/j.lanmic.2026.101401_bib76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41541-025-01286-8","article-title":"Post-attachment neutralization of HPV16 by antibodies derived from Gardasil-vaccinated women","volume":"10","author":"Day","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.lanmic.2026.101401_bib77","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ijc.29823","article-title":"Human papillomavirus capsids preferentially bind and infect tumor cells","volume":"138","author":"Kines","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.lanmic.2026.101401_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.2006601","article-title":"Heterogeneity and longevity of antibody memory to viruses and vaccines","volume":"16","author":"Antia","year":"2018","journal-title":"PLoS Biol"}],"container-title":["The Lancet Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266652472600056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266652472600056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:38:30Z","timestamp":1789360710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266652472600056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S266652472600056X"],"URL":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101401","relation":{},"ISSN":["2666-5247"],"issn-type":[{"value":"2666-5247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines","name":"articletitle","label":"Article Title"},{"value":"The Lancet Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanmic.2026.101401","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101401"}}